Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 6

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
 statements.

 6Table of Contents

ENDRA Life Sciences Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

  Six Months  Six Months   Ended  Ended   June 30,  June 30,   2025  2024 Cash Flows from Operating Activities      Net loss $(2,262,242) $(5,004,853)Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation and amortization  23,142   23,993 Fixed assets write off  -   8,808 Inventory reserve  -   4,687 Stock compensation expense  171,809   504,087 Amortization of right of use assets  55,231   81,807 Changes in fair value of warrant liability  (470,674)  - Changes in operating assets and liabilities:        Decrease in prepaid expenses  159,873   (134,312)Increase in inventory  -   (93,745)Decrease in accounts payable and accrued liabilities  (59,871)  466,680 Decrease in lease liability  (24,112)  (84,765)Net cash used in operating activities  (2,406,844)  (4,227,613)         Cash Flows from Investing Activities        Purchases of fixed assets  (17,280)  (16,000)Proceeds from sale of fixed assets  -   3,204 Net cash used in investing activities  (17,280)  (12,796)         Cash Flows from Financing Activities        Proceeds from issuance of common stock  1,003,218   1,148,470 Proceeds from warrant issuances and exercises  -   6,687,248 Repayment of loan  -   (28,484)Net cash provided by financing activities  1,003,218   7,807,234          Net decrease in cash  (1,420,906)  3,566,825          Cash, beginning of period  3,229,480   2,833,907          Cash, end of period $1,808,574